Rethinking 30-day readmission in adults with type 2 diabetes: the role of point-of-care ultrasound
Published
February 10, 2024
Paper ID
PAP-000020
Status
Published
DOI
10.65712/tmj.test000278
Advance Services
Abstract
Background: 30-day readmission remains a leading cause of avoidable harm among adults with type 2 diabetes. Methods: Missing data were handled with multiple imputation. Results: The adjusted odds ratio was 0.42 (95% CI 0.20 to 0.66). Serious adverse events were rare and similar between groups. Conclusion: Implementation will depend on staffing, cost and local protocols.
References
1. Patel I, Zhang U, et al. High-flow nasal oxygen and ventilator-free days. Lancet. 2008;60(11):134-1538.
2. Rossi O, Haddad L, et al. Nurse-led discharge planning and acute kidney injury. Lancet. 2008;184(12):105-1255.
3. Kim D, Zhang I, et al. Pharmacist-led medication review and chronic pain scores. Diabetes Care. 2024;251(3):434-1094.
4. Kim N, Mensah Q, et al. An enhanced recovery pathway and surgical site infection. Pediatrics. 2013;272(4):591-977.
5. Rossi B, Okafor P, et al. Nurse-led discharge planning and chronic pain scores. Eur Heart J. 2008;153(3):616-1473.
6. Dubois L, Nakamura V, et al. Vitamin D supplementation and health-related quality of life. BMJ. 2009;307(8):654-1434.
7. Zhang I, Mensah L, et al. An antibiotic stewardship programme and length of stay. Lancet. 2017;149(4):253-1752.
Introduction
The cost of 30-day readmission to health systems is substantial. Practice around point-of-care ultrasound varies widely between centres.
Practice around point-of-care ultrasound varies widely between centres.
Guidelines make only a weak recommendation on point-of-care ultrasound. Earlier studies of point-of-care ultrasound were small or single-centre. 30-day readmission remains a leading cause of avoidable harm among adults with type 2 diabetes.
Materials and Methods
We conducted a systematic review and meta-analysis across 3 centres between 2020 and 2025. We conducted a systematic review and meta-analysis across 13 centres between 2015 and 2022. Eligible participants were adults with type 2 diabetes.
Analyses were adjusted for age, sex and baseline severity. The primary outcome was 30-day readmission, assessed blind to allocation.
Results
The adjusted odds ratio was 0.45 (95% CI 0.23 to 0.78). Effects were consistent across prespecified subgroups. 1421 participants were included (median age 39 years).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Intervention | 516 | 64 | 22.6 | 0.84 |
| Age ≥ 65 | 528 | 118 | 34.8 | 0.91 |
| Control | 324 | 88 | 32.4 | 0.87 |
| Centre B | 832 | 70 | 18.2 | 0.86 |
| Age < 65 | 524 | 36 | 23.1 | 0.87 |
| Male | 708 | 81 | 19.6 | 0.75 |
Values are n (%) unless stated otherwise.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. 2027 participants were included (median age 78 years). Effects were consistent across prespecified subgroups.
30-day readmission occurred in 20% of the intervention group versus 35% of controls. The adjusted odds ratio was 0.79 (95% CI 0.39 to 0.65). 4318 participants were included (median age 44 years).
Discussion
Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.
These findings suggest that point-of-care ultrasound is associated with better 30-day readmission in adults with type 2 diabetes. Strengths include the sample size and blinded outcome assessment. Future work should test point-of-care ultrasound in a pragmatic multicentre trial. Residual confounding cannot be excluded.
Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded.
Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment. These findings suggest that point-of-care ultrasound is associated with better 30-day readmission in adults with type 2 diabetes.
Implementation will depend on staffing, cost and local protocols. Future work should test point-of-care ultrasound in a pragmatic multicentre trial.
Conclusions
Point-of-care ultrasound is a reasonable option for adults with type 2 diabetes to improve 30-day readmission.
Appendices
Ethics approval: IRB-4295.